ABI-4334 shows strong antiviral activity and favorable safety in Phase 1b study for chronic HBV, with data expected in 2025. ABI-4334 demonstrated strong antiviral activity with a mean reduction of ...
Study Achieves Primary and all Secondary Endpoints Demonstrating Clinically Meaningful, Statistically Significant Improvements in hrHPV Negativity at Week 12 as Compared to Placebo 46% of Patients ...
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo ...
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will ...
Assembly Biosciences, Inc. (NASDAQ:ASMB) released interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoing Phase 1a/b study of ABI-5366, an ...
(RTTNews) - Assembly Biosciences (ASMB), a biotechnology company focused on developing treatments for viral diseases, announced on Wednesday that the first participant has been dosed in its Phase 1a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback